MERZ-THERAPEUTICS
Merz Therapeutics announces today the successful acquisition of INBRIJA® (levodopa inhalation powder) and (F)AMPYRA® (fampridine), and related assets from Acorda Therapeutics, Inc. AMPYRA® (dalfampridine) is Food and Drug Administration (FDA) approved in the U.S. and commercialized as FAMPYRA in the European Union and other territories throughout the world. This transaction was conducted through a court-structured 363 sale under the U.S. Bankruptcy Code. The completion of this deal, valued at USD 185 million in cash, bolsters Merz Therapeutics’ market position by enhancing offerings for people living with Parkinson’s disease and expanding into the multiple sclerosis (MS) space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240710459851/en/
“The addition of INBRIJA and (F)AMPYRA to the treatment portfolio underlines Merz Therapeutics’ global Pivot for Growth strategy to both evolve the current portfolio and achieve critical scale and global reach,” said Stefan König, CEO of Merz Therapeutics. “Merz Therapeutics is well poised to build on what we have accomplished in the specialty neurology space, strengthening our market position in Parkinson’s disease and expanding into the MS segment. This deal demonstrates Merz Therapeutics’ interest and ability to acquire assets that will deliver greater, sustainable outcomes for more people living with neurological disorders.”
INBRIJA and (F)AMPYRA are projected to immediately add topline revenue which will enhance Merz Therapeutics’ ability to accelerate clinical development of its existing and new assets. Its U.S. business is forecasted to contribute more than 75% of INBRIJA’s and (F)AMPYRA’s total global revenues over the next 10 years. Additionally, the company expects the U.S. workforce to increase by more than 50%.
INBRIJA is a significant advancement for people living with Parkinson's disease as it provides an on-demand, inhalable form of levodopa, offering an effective way to manage “OFF” episodes. This method of delivery, achievable through the innovative and proprietary technology platform, ARCUS®, is especially valuable for people who need rapid relief from their symptoms, which cannot be achieved reliably through oral intake.
(F)AMPYRA is the first medication approved for improving walking in patients with MS, demonstrated by an improved walking ability.
“Expanding the portfolio with INBRIJA, including plans for worldwide product roll-out, and (F)AMPYRA allows Merz Therapeutics the opportunity to leverage its experience in the specialty neurology space to serve even more patients living with neurological disorders and support the physicians who treat them,” said Stefan Albrecht, Chief Scientific and Medical Officer. “Because these treatments complement the company’s product portfolio and distribution system, we are well positioned to support patients who depend on these products seamlessly.”
About INBRIJA
INBRIJA® is an inhaled prescription levodopa medicine used to treat the return of Parkinson’s symptoms (known as “OFF” episodes) in people with Parkinson’s disease who are treated with carbidopa/levodopa medicines. It does not replace the regular carbidopa/levodopa medicines. INBRIJA is not to be used by people with Parkinson’s disease who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine, within the last 2 weeks. The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea and change in the color of saliva or spit.
About FAMPYRA
FAMPYRA® is a prolonged-release (sustained release) tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine). FAMPYRA is indicated in the European Union for the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS 4-7). In clinical trials, the highest incidence of adverse reactions identified with FAMPYRA given at the recommended dose was urinary tract infection. Other adverse drug reactions identified were mainly divided between neurological disorders such as insomnia, balance disorder, dizziness, paraesthesia and headache, and gastrointestinal disorders including nausea, dyspepsia and constipation. In post-marketing experience, there have been reports of seizure. Please see FAMPYRA EPAR for more information.
About AMPYRA
AMPYRA® is an extended-release tablet formulation of dalfampridine (4-aminopyridine, 4-AP or fampridine). AMPYRA is a potassium channel blocker approved as a treatment to help improve walking in adults with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. The most common side effects for AMPYRA in MS patients were urinary tract infection; trouble sleeping; dizziness; headache; nausea; weakness; back pain; problems with balance; multiple sclerosis relapse; burning, tingling, or itching of your skin; irritation in your nose and throat; constipation; indigestion; and pain in your throat. Please see the AMPYRA Patient Medication Guide for more information.
About Merz Therapeutics
Merz Therapeutics is dedicated to improving the lives of patients around the world. With its relentless research, development and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs.
Please visit www.merztherapeutics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710459851/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Saudi Arabia to Host World Economic Forum Global Collaboration and Growth Meeting: Building Common Ground and Reviving Growth on 22-23 April 202623.1.2026 16:29:00 CET | Press release
Saudi Arabia will host the World Economic Forum (WEF) Global Collaboration and Growth Meeting: Building Common Ground and Reviving Growth in Jeddah on 22-23 April 2026, it was announced on the closing day of the 56th Annual Meeting of the Forum in Davos, Switzerland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123725881/en/ HE Faisal F. Alibrahim, Saudi Arabia’s Minister of Economy and Planning, announces that the Kingdom will host the World Economic Forum Global Collaboration and Growth Meeting in Jeddah in April 2026 (Photo: AETOSWire) His Excellency Faisal F. Alibrahim, Saudi Arabia’s Minister of Economy and Planning today confirmed the details for the regular high-level WEF meeting, which was announced at the 2025 WEF Annual Meeting. Calling for pragmatism and collaboration against a backdrop of geopolitical fragmentation, HE Alibrahim said “stability can’t be quickly built, and it can’t be bought”. “Stability need
Philip Morris International Urges FDA Advisory Committee to Recommend Authorizing ZYN as a Modified Risk Tobacco Product23.1.2026 15:15:00 CET | Press release
In January 2025, ZYN became the first nicotine pouch product authorized for marketing by the FDA Experts from Philip Morris International (PMI) (NYSE: PM) yesterday presented scientific evidence to the U.S. Food and Drug Administration’s (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) as part of the FDA’s process for a Modified Risk Tobacco Product (MRTP) designation for their ZYN nicotine pouch products. This designation would allow PMI’s U.S. family of businesses to communicate to U.S. legal-aged, 21+ adult cigarette smokers that switching completely to ZYN reduces their risk of many smoking-related diseases and we look forward to a decision by FDA. "The FDA’s Center for Tobacco Product’s (CTP) mission is to make smoking-related disease and death a part of America’s past,” said Keagan Lenihan, Chief External Affairs Officer for PMI U.S. “Smoke-free products, like ZYN, play a critical role in helping CTP achieve this mission and provide adults who smoke with important inf
Business4Land Champions’ Council Launched at Davos to Spur Private Sector Action on Land and Drought23.1.2026 14:58:00 CET | Press release
The UNCCD COP16 Presidency, led by Saudi Arabia, and the United Nations Convention to Combat Desertification (UNCCD) Secretariat launched the Business4Land (B4L) Champions’ Council at the World Economic Forum in Davos to mobilize global CEOs and industry leaders in support of large-scale land restoration. The B4L Champions Council members include ten companies: Nexira, Suzano, Gut & Bösel, Patagonia Provisions/ B.Cameron Consulting, Olam Group, Reservas Votorantim, Genesis Soil Health, EY, Envision Energy, and LVMH The move marks the beginning of a more structured and strategic engagement with the private sector ahead of COP17. TheUnited Nations Convention to Combat Desertification(UNCCD) Secretariat and the UNCCD COP16 Presidency, led by the Kingdom of Saudi Arabia, today announced the official launch of the Business4Land (B4L) Champions’ Council at a high-level event hosted at InTent during the World Economic Forum (WEF) Annual Meeting in Davos. This press release features multimedia
WEF26: Saudi Arabia Becoming ‘A Connector Economy’ as World Trade Evolves23.1.2026 14:47:00 CET | Press release
His Excellency Majid A. Alkassabi, Saudi Arabia’s Minister of Commerce, today at the World Economic Forum Annual Meeting in Davos said the Kingdom stands to benefit from ongoing shifts in global supply chains. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123425621/en/ Amid shifting global trade dynamics, Saudi Arabia underscores its role as a stable connector economy linking markets across regions (Photo: AETOSWire) Speaking in a session titled ‘Many Shapes of Trade’, HE commented: “Trade today is definitely shifting from fair trade to a managed and rule-driven trade model. For us in Saudi Arabia, we have a strategic location, we have a lot of resources, we could become a bridge economy. We could become a connector economy where we can connect with Africa, with Europe, with Asia, becoming a logistic hub.” His Excellency Ahmed A. Alkhateeb, Minister of Tourism, in a session called ‘The New Geography of Travel: Elevating
Andersen Consulting styrker sit udbud inden for digital transformation med Silver Creek23.1.2026 14:25:00 CET | Pressemeddelelse
Andersen Consulting annoncerer en samarbejdsaftale med Silver Creek, en førende virksomhed inden for datastrategi, analyse, applikationsudvikling og ai-drevne automatiseringstjenester. Silver Creek Software er en førende teknologivirksomhed, der er baseret i Alberta, Canada, med ekspertise i at transformere organisationer gennem data- og forretningsløsninger. Firmaet blev etableret i 1998 og tilbyder komplette konsulentydelser med speciale i data og analyse, applikationsudvikling, maskinlæring og ai. Med et team af erfarne og certificerede fagfolk leverer virksomheden skræddersyede løsninger på tværs af flere brancher, herunder den offentlige sektor, finansielle tjenester, naturressourcer og transport. Kernen i Silver Creeks arbejde er at skabe værdi ud fra kundens data gennem digitalisering, integration og automatisering. "Vi har opbygget vores omdømme på at hjælpe organisationer med at omdanne komplekse dataøkosystemer til strategiske aktiver," udtaler Ben Steem, administrerende dire
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom